← brief for 2026-09-04 · Slowing decline

Early laboratory trajectories and short-term tolerability after finerenone initiationin diabetic kidney disease: the multicenter FINE-TURK study.

Article C Peer reviewed Observational

Key takeaways

Doctors in Turkey looked back at hospital records of adults with diabetes and kidney disease who started finerenone, a drug that blocks a hormone signal that scars the kidney. They tracked early changes in kidney filtering rate, potassium in the blood, and protein in the urine, plus who stopped the drug. Most patients were also on SGLT2 inhibitor drugs, so this shows how finerenone behaves in real practice today. There was no comparison group, so this shows a pattern, not proof that the drug caused what happened.

Who did this work

Yadigar S · Akgür S · Arslan F · Sezen M · Özcan B · Ayaz EY · Doğantekin B · Atay İ · Değer SM · Demir M · Koyuncu S · Yılmaz Ü

Source

Article · PubMed, the drug frontier · 2026 Aug 21
https://pubmed.ncbi.nlm.nih.gov/42693414/